
Penarth dementia event takes place as UK cases near million
The event came with one shared mission, to turn Penarth into a more inclusive, informed space for people living with dementia.
Mayor Emma Richards with Phil Batchelor and local community lead Miles Utting. (Image: Phil Batchelor) The event was officially opened by Penarth's newly elected mayor, Emma Richards, who stood alongside Dementia Friendly Penarth chair Phil Batchelor and local community lead Miles Utting.
More than 20 organisations participated, offering resources, support, and hands-on advice to residents and caregivers. Groups included the Cardiff & Vale NHS Memory Team, Alzheimer's Society, Marie Curie, Telecare, South Wales Police and Penarth Library among many others.
The Alzheimer's Society at The Paget Rooms on Thursday, May 22nd. (Image: Phil Batchelor)
Mr Batchelor said: "What truly moved me during these discussions was hearing first hand how community members felt empowered by sharing their experiences.
"It reminded me that our strength lies in coming together and caring for one another."
According to the latest estimates from Alzheimer's Research UK, nearly 1 million people in the UK are currently living with dementia, a figure expected to soar to 1.4 million by 2040.
New data from the Office for National Statistics reveals that more than 47,000 people across Wales are currently living with a diagnosed case of dementia. Urban and coastal regions are seeing substantially higher rates.
One such hotspot is the Vale of Glamorgan, where an estimated 2,300 to 3,400 people are living with dementia.
NHS information desk at The Paget Rooms on Thursday, May 22nd. (Image: Phil Batchelor)
Research from the 2023 Dementia Attitudes Monitor reveals only 36 per cent of the UK public believe it's possible to reduce the risk of developing dementia, despite evidence suggesting that up to 40 per cent of cases are linked to modifiable lifestyle factors like exercise, diet, and smoking.
The campaign's theme, Turning Penarth Blue, was a call to action, designed to paint the town with compassion, resources, and real understanding of the challenges people with dementia face every day.
While more than half of adults in the UK know someone with dementia, many still fail to recognise it as a terminal condition. Only 60 per cent of the public accept that dementia is a cause of death, according to national surveys.
Mr Batchelor said: "We're changing that narrative. With support, research, and awareness, we can all be part of creating a better future, for Penarth, for Wales, and for the thousands of families affected by dementia every year."
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


BBC News
10 hours ago
- BBC News
Capivasertib given to breast cancer patients in Wales for first time
A drug which has been proven to extend the life of some people with incurable breast cancer has been given to patients on the NHS in Wales for the first Buchan, 62, who has terminal breast cancer, said capivasertib would allow her to see her son's wedding and gave her "hope".Half of women with breast cancer fuelled by the hormone oestrogen are likely to see their life expectancy double when capivasertib is combined with hormone therapy, research has Rob Jones, who co-led a study looking at capivasertib's effectiveness, said the drug offered "a real life impact for people to spend extra time with their relatives, with their friends". Breast cancer is the most common cancer in the UK, with one in seven women affected in their lifetimes and 75% surviving for 10 years or more after Wales, more than 2,000 people are diagnosed with breast cancer every which was developed by experts at Velindre Cancer Centre and Cardiff University, became available to breast cancer patients on the NHS in April. When Ms Buchan's first line of treatment for her terminal breast cancer stopped working, it was a the recent approval of capivasertib for use on the NHS alongside hormone therapy will allow her to enjoy more time with family and has a common genetic abnormality in her cancer which tests have shown responds well to the drug."To be told I had secondary breast cancer but my life can be extended, I think it's that hope you have to keep in your mind," said Ms Buchan from Barry, Vale of Glamorgan."I know that prior to the first line of treatment going down it was expected I'd live five or six years, maybe more. "The way I cope with this is by thinking about today and today is a good day."Ms Buchan is among thousands in the UK and millions worldwide who could benefit from the drug."I think I'm really lucky because I've got the most supportive husband, children and their partners and extended family and wonderful friends. "What this drug can do for me is allow me to see my son's wedding next year and to look into the future." Despite its approval for use globally by the US Food and Drug Administration (FDA) in 2023, capivasertib only became available to patients via the NHS in England and Wales this Simon Waters, consultant medical oncologist at Velindre Cancer Centre, said it was a "great opportunity now we've got to this point". "People have been working on it for a long time. It's great we can now put it in to practice as a standard treatment," he said. "We've been using a similar treatment for a smaller group of patients for a few years and that's had quite a lot of issues with side effects and we think this treatment will not only be more effective but also will have fewer issues with side effects. "It's also applicable to a larger group of patients with this common type of breast cancer." How does capivasertib work? The drug is suitable for those with certain gene mutations that affect up to half of people with hormone receptor positive secondary breast cancer - the most common type, which grows in the presence of hormone therapy usually works, eventually the cancer can become resistant to it.A clinical trial found a particular protein which drives the resistance can be neutralised when hormone therapy is combined with capivasertib. 'Doubling of survival time' Prof Rob Jones said: "Patients who received the hormone therapy with a placebo had an overall survival of around 20 months and those who received the capivasertib with the hormone therapy had an extra 39 months."It really is a doubling of survival time so that really is significant. It's not just a statistic - it's a real life impact for people to spend extra time with their relatives, with their friends."Dr Nicola Williams, national director of support and delivery at Health and Care Research Wales, said: "A breast cancer diagnosis can be devastating and one in seven women will be diagnosed with the disease in their lifetime. "This diagnosis is even more painful if you're told your cancer is incurable. "Thanks to the trial and the licensing of capivasertib, when used alongside a standard hormonal therapy, patients like Gwen now have the potential to receive a very significant extension in their lifespan and improved quality of life."


Telegraph
21 hours ago
- Telegraph
Live England vs West Indies: Score and latest updates from second ODI
Latest updates live updates 01 June 2025 10:35am 10:35AM Team news One change apiece. Matt Potts comes in for the injured Jamie Overton. West Indies are still without Evin Lewis, but Shimron Hetmyer replaces Amir Jangoo. England Smith, Duckett, Root, Brook (c), Buttler (wk), Bethell, Jacks, Carse, Potts, Rashid, Mahmood. West Indies King, Andrew, Carty, Hope (c/wk), Hetmyer, Greaves, Chase, Forde, Motie, A Joseph, Seales. 10:32AM England win the toss and bowl Harry Brook says there's a little bit of live grass and hopes England can get something out of the pitch early on. Nasser Hussain asks Shai Hope what he would have done. 'Doesn't really matter now, does it?!' is the reply. 10:12AM Good morning Hello and welcome to Telegraph Sport's live, over-by-over coverage of the second ODI between England and West Indies at Cardiff. White-ball cricket moves pretty fast: three days on from his first game as full-time captain, Harry Brook has a chance to wrap up his first series victory. England were excellent at Edgbaston, marmalising a poor West Indies by 238 runs, with Jacob Bethwell and Saqib Mahmood outstanding. Brook will want more of the same, though England have been forced into one change after Jamie Overton suffered a broken finger in that first game. He joins an injury list that includes Jofra Archer, Gus Atkinson, Mark Wood, Olly Stone and more. But even with all those injuries, England are able to bring in a bowler of Matt Potts' quality. He was impressive in last year's ODI series against Australia and has been unfortunate not to play an ODI since then. England have decided not to call up a replacement, which means Lancashire's Luke Wood is the spare seamer for the remainder of the series, which concludes at The Oval on Tuesday. 'That was a phenomenal performance from the boys,' said Brook at Edgbaston. 'There were four of us that got 50+ scores, if one of us kicked on from there, that would have bee] a pretty complete performance.' West Indies are likely to bring back the dangerous opener Evin Lewis, who was injured in the warm-up before the first ODI at Edgbaston. There is a chance of rain today, though it's unlikely to have a major impact. The match starts at 11am, with the toss at 10.30am.


Daily Mail
2 days ago
- Daily Mail
England seamer Saqib Mahmood confident he can play a leading role in new white-ball era under Harry Brook - as he reveals delight with his injury recovery
Saqib Mahmood is confident he can play a leading role in England's new white-ball era – thanks to his versatility. The Lancashire seamer took three wickets with the new ball as England thrashed West Indies at Edgbaston on Thursday in the first match of Harry Brook's captaincy. And Mahmood believes his ability to swing the ball both ways, as well as being able to bowl at both the start and end of an innings, can make him a key component in Brook's attack. 'I feel like I'm quite versatile in what I try,' said the 28-year-old ahead of the second ODI in Cardiff. 'From one end at Edgbaston, I was trying to swing the ball back in with the breeze. Then when I came on at the other end, I found I could swing the ball away as well. 'I try to cover all bases, especially with that new ball. That's my way of helping out the team. That's what I feel like my role is here. And I obviously have my skills at the backend as well.' Mahmood was not awarded an ECB central contract at the end of last year, which could have signalled the beginning of the end of his international career. However, the pace bowler appears to be back to his best after recovering from successive stress fractures dating back to spring 2022. 'I don't want to say I'm stronger than ever because I feel like I'm jinxing it,' said Mahmood. 'But since coming back from those back injuries, this is the most I've put through my body and it's tolerated it pretty well. 'I've managed to string a lot of cricket over the last 12 months and I'm just happy about that.' Despite signing a white-ball only deal with Lancashire last autumn, Mahmood made two County Championship appearances earlier this season. However, he claimed just two wickets on batting-friendly surfaces at Old Trafford and is realistic about his chances of adding to his two Test caps. 'It was good that I got some overs under my belt for Lancs, but they were two pretty hard wickets to bowl on,' added Mahmood. 'They didn't really give me the best chance to try and get some wickets. 'But I'm just trying to do well here at the moment. The main focus is this series and the T20s. But he is refusing to get carried away as he looks to add to his two Test caps to date 'I'm not really looking too far ahead of that because there's just so much competition in the team and you want to do the best you can. 'You don't really want to take your eye off it and look too far ahead. So my main focus is the here and now and I don't want to take my eye off the action.'